arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aquestive Therapeutics, Inc.

AQST
$4.70 ▼ -0.25 (-4.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

Aquestive Therapeutics, Inc. shows mixed fundamentals. However, watch Operating Margin (%) and Profit Margin (%) which show concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $587.5M
Dividend Yield
Revenue Growth 38.1%
Op. Margin -59.5%
ROIC 518.5%
FCF / Share $-0.08
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.97
info Valuation on last close. End-of-day price, Sep 23, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.82M
↑ +38.1%
Net Income Profit after all expenses
$-8.06M
↑ +64.9%
Operating Margin Operating profit as % of sales
-59.5%
↓ -104.5% 1th
FCF / Share Free cash flow per share
$-0.08
↑ +36.3%
Long-Term Debt Long-term obligations
$55.00M
↑ +22.2%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
100
Financial Health
64
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 39 quarters